Precipio (NASDAQ: PRPO) is one of 186 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare Precipio to related businesses based on the strength of its risk, profitability, valuation, dividends, earnings, analyst recommendations and institutional ownership.
Volatility & Risk
Precipio has a beta of -0.1, indicating that its share price is 110% less volatile than the S&P 500. Comparatively, Precipio’s competitors have a beta of 1.53, indicating that their average share price is 53% more volatile than the S&P 500.
This table compares Precipio and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Precipio||$1.55 million||-$7.61 million||-0.06|
|Precipio Competitors||$217.36 million||-$39.57 million||-59.68|
Precipio’s competitors have higher revenue, but lower earnings than Precipio. Precipio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Precipio and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and price targets for Precipio and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.18%. Given Precipio’s competitors higher probable upside, analysts clearly believe Precipio has less favorable growth aspects than its competitors.
Institutional & Insider Ownership
14.5% of Precipio shares are held by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 1.9% of Precipio shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Precipio competitors beat Precipio on 7 of the 10 factors compared.
Precipio Company Profile
Precipio, Inc., formerly Transgenomic, Inc., is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted.
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.